Showing results (451-460 of 511) with videos related to

Sort By:
Pageof 52
JTO Clinical and Research Reports|May 31, 2022
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional ExperienceA J Piper-Vallillo, Julia K Rotow, Jacqueline V Aredo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.
Cancer Reports (Hoboken, N.J.)|August 28, 2025
Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast CancerSeema Nagpal, Kim-Son Nguyen, Sophie Bertrand, et al.
Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancerNatalie J Miller, Christina S Baik, Joel W Neal, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2017
Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancerMichael F Gensheimer, Julian C Hong, Christine Chang-Halpenny, et al.
Lab on a Chip|August 24, 2013
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochipsChristopher M Earhart, Casey E Hughes, Richard S Gaster, et al.
Circulation Research|February 11, 2025
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy MyocarditisYuhsin Vivian Huang, Yin Sun, Harrison Chou, et al.
Clinical Lung Cancer|July 14, 2023
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never SmokedJ Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2024
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPYMaja Ivanovic, Antonia Chan, Evaline Cheng, et al.
Pageof 52